Yeramian Patrick D's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed May 17, 2023
- Accession no.
- 0000950170-23-022775
- Filed
- May 17, 2023, 4:58 PM ET
- Trade date
- May 15, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $347.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yeramian Patrick DCIK 0001358266 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Common Stock | MOption exerciseAcquired | +2,201 | $0.37 | +$814.37 | 210,618 | Direct | |
| May 15, 2023 | Common Stock | MOption exerciseAcquired | +9,764 | $6.88 | +$67,176.32 | 220,382 | Direct | |
| May 15, 2023 | Common Stock | SSaleDisposed | −11,965 | $29.03F2 | −$347,358.31 | 208,417 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Common Stock | MOption exerciseDisposed | −2,201 | $0.00 | $0 | 15,404 | Direct | |
| May 15, 2023 | Common Stock | MOption exerciseDisposed | −9,764 | $0.00 | $0 | 33,770 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.